The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
CAR-T Cell Immunotherapies for Cancer-Global Market Insights and Sales Trends 2024
Synopsis
The global CAR-T Cell Immunotherapies for Cancer market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of CAR-T Cell Immunotherapies for Cancer in various end use industries. The expanding demands from the Hematological Cancer, Solid Tumor and Other Oncological Disorders,, are propelling CAR-T Cell Immunotherapies for Cancer market. CD19, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the BCMA segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for CAR-T Cell Immunotherapies for Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global CAR-T Cell Immunotherapies for Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global CAR-T Cell Immunotherapies for Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, CAR-T Cell Immunotherapies for Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of CAR-T Cell Immunotherapies for Cancer covered in this report include NOVARTIS, Penn, Fosun Pharma, Celgene Corporation, Legend Biotech, SHEBA, JW Therapeutics, Protheragen and EXUMA Biotechnology, etc.
The global CAR-T Cell Immunotherapies for Cancer market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
NOVARTIS
Penn
Fosun Pharma
Celgene Corporation
Legend Biotech
SHEBA
JW Therapeutics
Protheragen
EXUMA Biotechnology
Global CAR-T Cell Immunotherapies for Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global CAR-T Cell Immunotherapies for Cancer market, Segment by Type:
CD19
BCMA
EPCAM
Global CAR-T Cell Immunotherapies for Cancer market, by Application
Hematological Cancer
Solid Tumor
Other Oncological Disorders
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of CAR-T Cell Immunotherapies for Cancer companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global CAR-T Cell Immunotherapies for Cancer market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of CAR-T Cell Immunotherapies for Cancer in various end use industries. The expanding demands from the Hematological Cancer, Solid Tumor and Other Oncological Disorders,, are propelling CAR-T Cell Immunotherapies for Cancer market. CD19, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the BCMA segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for CAR-T Cell Immunotherapies for Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global CAR-T Cell Immunotherapies for Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global CAR-T Cell Immunotherapies for Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, CAR-T Cell Immunotherapies for Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of CAR-T Cell Immunotherapies for Cancer covered in this report include NOVARTIS, Penn, Fosun Pharma, Celgene Corporation, Legend Biotech, SHEBA, JW Therapeutics, Protheragen and EXUMA Biotechnology, etc.
The global CAR-T Cell Immunotherapies for Cancer market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
NOVARTIS
Penn
Fosun Pharma
Celgene Corporation
Legend Biotech
SHEBA
JW Therapeutics
Protheragen
EXUMA Biotechnology
Global CAR-T Cell Immunotherapies for Cancer market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global CAR-T Cell Immunotherapies for Cancer market, Segment by Type:
CD19
BCMA
EPCAM
Global CAR-T Cell Immunotherapies for Cancer market, by Application
Hematological Cancer
Solid Tumor
Other Oncological Disorders
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of CAR-T Cell Immunotherapies for Cancer companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of CAR-T Cell Immunotherapies for Cancer
1.1 CAR-T Cell Immunotherapies for Cancer Market Overview
1.1.1 CAR-T Cell Immunotherapies for Cancer Product Scope
1.1.2 CAR-T Cell Immunotherapies for Cancer Market Status and Outlook
1.2 Global CAR-T Cell Immunotherapies for Cancer Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global CAR-T Cell Immunotherapies for Cancer Market Size by Region (2018-2029)
1.4 Global CAR-T Cell Immunotherapies for Cancer Historic Market Size by Region (2018-2023)
1.5 Global CAR-T Cell Immunotherapies for Cancer Market Size Forecast by Region (2024-2029)
1.6 Key Regions, CAR-T Cell Immunotherapies for Cancer Market Size (2018-2029)
1.6.1 North America CAR-T Cell Immunotherapies for Cancer Market Size (2018-2029)
1.6.2 Europe CAR-T Cell Immunotherapies for Cancer Market Size (2018-2029)
1.6.3 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size (2018-2029)
1.6.4 Latin America CAR-T Cell Immunotherapies for Cancer Market Size (2018-2029)
1.6.5 Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size (2018-2029)
2 CAR-T Cell Immunotherapies for Cancer Market by Type
2.1 Introduction
2.1.1 CD19
2.1.2 BCMA
2.1.3 EPCAM
2.2 Global CAR-T Cell Immunotherapies for Cancer Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global CAR-T Cell Immunotherapies for Cancer Historic Market Size by Type (2018-2023)
2.2.2 Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America CAR-T Cell Immunotherapies for Cancer Revenue Breakdown by Type (2018-2029)
2.3.2 Europe CAR-T Cell Immunotherapies for Cancer Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America CAR-T Cell Immunotherapies for Cancer Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa CAR-T Cell Immunotherapies for Cancer Revenue Breakdown by Type (2018-2029)
3 CAR-T Cell Immunotherapies for Cancer Market Overview by Application
3.1 Introduction
3.1.1 Hematological Cancer
3.1.2 Solid Tumor
3.1.3 Other Oncological Disorders
3.2 Global CAR-T Cell Immunotherapies for Cancer Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global CAR-T Cell Immunotherapies for Cancer Historic Market Size by Application (2018-2023)
3.2.2 Global CAR-T Cell Immunotherapies for Cancer Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America CAR-T Cell Immunotherapies for Cancer Revenue Breakdown by Application (2018-2029)
3.3.2 Europe CAR-T Cell Immunotherapies for Cancer Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America CAR-T Cell Immunotherapies for Cancer Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa CAR-T Cell Immunotherapies for Cancer Revenue Breakdown by Application (2018-2029)
4 CAR-T Cell Immunotherapies for Cancer Competition Analysis by Players
4.1 Global CAR-T Cell Immunotherapies for Cancer Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in CAR-T Cell Immunotherapies for Cancer as of 2022)
4.3 Date of Key Players Enter into CAR-T Cell Immunotherapies for Cancer Market
4.4 Global Top Players CAR-T Cell Immunotherapies for Cancer Headquarters and Area Served
4.5 Key Players CAR-T Cell Immunotherapies for Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 CAR-T Cell Immunotherapies for Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 NOVARTIS
5.1.1 NOVARTIS Profile
5.1.2 NOVARTIS Main Business
5.1.3 NOVARTIS CAR-T Cell Immunotherapies for Cancer Products, Services and Solutions
5.1.4 NOVARTIS CAR-T Cell Immunotherapies for Cancer Revenue (US$ Million) & (2018-2023)
5.1.5 NOVARTIS Recent Developments
5.2 Penn
5.2.1 Penn Profile
5.2.2 Penn Main Business
5.2.3 Penn CAR-T Cell Immunotherapies for Cancer Products, Services and Solutions
5.2.4 Penn CAR-T Cell Immunotherapies for Cancer Revenue (US$ Million) & (2018-2023)
5.2.5 Penn Recent Developments
5.3 Fosun Pharma
5.3.1 Fosun Pharma Profile
5.3.2 Fosun Pharma Main Business
5.3.3 Fosun Pharma CAR-T Cell Immunotherapies for Cancer Products, Services and Solutions
5.3.4 Fosun Pharma CAR-T Cell Immunotherapies for Cancer Revenue (US$ Million) & (2018-2023)
5.3.5 Celgene Corporation Recent Developments
5.4 Celgene Corporation
5.4.1 Celgene Corporation Profile
5.4.2 Celgene Corporation Main Business
5.4.3 Celgene Corporation CAR-T Cell Immunotherapies for Cancer Products, Services and Solutions
5.4.4 Celgene Corporation CAR-T Cell Immunotherapies for Cancer Revenue (US$ Million) & (2018-2023)
5.4.5 Celgene Corporation Recent Developments
5.5 Legend Biotech
5.5.1 Legend Biotech Profile
5.5.2 Legend Biotech Main Business
5.5.3 Legend Biotech CAR-T Cell Immunotherapies for Cancer Products, Services and Solutions
5.5.4 Legend Biotech CAR-T Cell Immunotherapies for Cancer Revenue (US$ Million) & (2018-2023)
5.5.5 Legend Biotech Recent Developments
5.6 SHEBA
5.6.1 SHEBA Profile
5.6.2 SHEBA Main Business
5.6.3 SHEBA CAR-T Cell Immunotherapies for Cancer Products, Services and Solutions
5.6.4 SHEBA CAR-T Cell Immunotherapies for Cancer Revenue (US$ Million) & (2018-2023)
5.6.5 SHEBA Recent Developments
5.7 JW Therapeutics
5.7.1 JW Therapeutics Profile
5.7.2 JW Therapeutics Main Business
5.7.3 JW Therapeutics CAR-T Cell Immunotherapies for Cancer Products, Services and Solutions
5.7.4 JW Therapeutics CAR-T Cell Immunotherapies for Cancer Revenue (US$ Million) & (2018-2023)
5.7.5 JW Therapeutics Recent Developments
5.8 Protheragen
5.8.1 Protheragen Profile
5.8.2 Protheragen Main Business
5.8.3 Protheragen CAR-T Cell Immunotherapies for Cancer Products, Services and Solutions
5.8.4 Protheragen CAR-T Cell Immunotherapies for Cancer Revenue (US$ Million) & (2018-2023)
5.8.5 Protheragen Recent Developments
5.9 EXUMA Biotechnology
5.9.1 EXUMA Biotechnology Profile
5.9.2 EXUMA Biotechnology Main Business
5.9.3 EXUMA Biotechnology CAR-T Cell Immunotherapies for Cancer Products, Services and Solutions
5.9.4 EXUMA Biotechnology CAR-T Cell Immunotherapies for Cancer Revenue (US$ Million) & (2018-2023)
5.9.5 EXUMA Biotechnology Recent Developments
6 North America
6.1 North America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe CAR-T Cell Immunotherapies for Cancer Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific CAR-T Cell Immunotherapies for Cancer Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America CAR-T Cell Immunotherapies for Cancer Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa CAR-T Cell Immunotherapies for Cancer Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 CAR-T Cell Immunotherapies for Cancer Market Dynamics
11.1 CAR-T Cell Immunotherapies for Cancer Industry Trends
11.2 CAR-T Cell Immunotherapies for Cancer Market Drivers
11.3 CAR-T Cell Immunotherapies for Cancer Market Challenges
11.4 CAR-T Cell Immunotherapies for Cancer Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
